AnaptysBio/ US0327241065 /
2024-05-21 9:59:56 PM | Chg. -1.14 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
23.89USD | -4.54% | 7,606 Turnover: 186,393.87 |
-Bid Size: - | -Ask Size: - | 25.21 | 23.89 |
GlobeNewswire
05-09
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-09
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) ...
GlobeNewswire
05-09
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sag...
GlobeNewswire
03-26
Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Cl...
GlobeNewswire
03-11
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
02-29
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
GlobeNewswire
2023-11-27
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Po...
GlobeNewswire
2023-11-11
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of AnaptysBio, Inc. (NASDAQ: ANAB) and En...
GlobeNewswire
2023-11-07
INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into AnaptysBio, Inc.; Urges AnaptysBio’s...
GlobeNewswire
2023-11-02
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
2023-10-11
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
GlobeNewswire
2023-10-09
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 2...
GlobeNewswire
2023-10-09
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Genera...
GlobeNewswire
2023-09-18
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
GlobeNewswire
2023-09-12
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
GlobeNewswire
2022-03-14
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne